DEFA14A: Alkermes CEO Reassures Avadel Employees on Merger

Alkermes CEO Richard Pops sent a message to Avadel Pharmaceuticals employees, expressing excitement for the upcoming acquisition and integration, and outlining future plans.

Summary

• Alkermes CEO Richard Pops sent an email to Avadel Pharmaceuticals employees on December 19, 2025, regarding the ongoing acquisition.
• The message expressed excitement for the year ahead (2026) and the integration of the two companies.
• Management believes there is significant potential in complementary strengths to benefit patients with serious hypersomnolence disorders.
• A virtual town hall is planned for late January 2026 to address employee questions and introduce Alkermes senior leaders.
• The communication acknowledges that periods of change can be unsettling but commits to transparency within Irish Takeover Rules guidelines.

Sentiment

Score: 7

Explanation: The communication is generally positive and reassuring, focusing on future potential and commitment to employees during an acquisition. It acknowledges the unsettling nature of change but frames it within an optimistic outlook for integration and patient impact. The tone is positive about the merger's benefits.

Positives

• Alkermes sees significant potential in the complementary strengths of both companies.
• The acquisition is expected to amplify impact on patients suffering from serious hypersomnolence disorders.
• Management is committed to transparency with employees regarding the integration process.
• A virtual town hall is scheduled for late January 2026 to engage with Avadel employees and introduce Alkermes leadership.

Negatives

• Management acknowledges that periods of change, such as an acquisition, can be unsettling for employees.

Risks

• The ability of the parties to consummate the Acquisition in a timely manner or at all.
• The satisfaction (or waiver) of conditions to the consummation of the Acquisition, including with respect to the approval of Avadel shareholders.
• The possibility that more competing offers for Avadel may be made.
• Potential delays in consummating the Acquisition.
• The ability of Avadel to timely and successfully achieve the anticipated benefits of the Acquisition.
• The impact of health pandemics on the parties' respective businesses.
• The occurrence of any event, change, or other circumstance or condition that could give rise to the termination of the Transaction Agreement.
• The effect of the pendency of the Acquisition on Avadel's or Alkermes' business relationships, operating results, and business generally.
• Costs related to the Acquisition.
• The outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the Transaction Agreement or the Acquisition.

Future Outlook

Alkermes and Avadel are looking forward to a successful integration in 2026, leveraging complementary strengths to amplify their impact on patients suffering from serious hypersomnolence disorders. A virtual town hall is planned for late January 2026 to facilitate this integration and address employee concerns.

Management Comments

• "We are excited about the year ahead." Richard Pops, CEO Alkermes
• "Our teams across both companies are working toward closing the acquisition and integrating two high performing organizations." Richard Pops, CEO Alkermes
• "We see significant potential in our complementary strengths and believe we can leverage those strengths to benefit patients and their families." Richard Pops, CEO Alkermes
• "I am confident that, working together, our teams and capabilities can amplify our impact on patients suffering from serious hypersomnolence disorders." Richard Pops, CEO Alkermes
• "We are committed to being as transparent and open with you as possible." Richard Pops, CEO Alkermes

Industry Context

This communication is part of the standard process for a pharmaceutical company acquisition, aiming to reassure employees and outline the integration strategy post-merger. The focus on 'serious hypersomnolence disorders' indicates a strategic alignment in a specific therapeutic area within the broader pharmaceutical industry.

Stakeholder Impact

• Shareholders: Will vote on the acquisition (as per Definitive Proxy Statement).
• Employees: Reassurance during the acquisition process, integration into Alkermes, potential for amplified impact in their work.
• Patients: Expected benefit from the combined companies' complementary strengths in treating serious hypersomnolence disorders.

Next Steps

• Closing the acquisition of Avadel by Alkermes.
• Integrating the two organizations.
• Holding a virtual town hall in late January 2026 for Avadel employees.
• Introducing Alkermes senior leaders to Avadel employees.

Key Dates

Keywords

Avadel Pharmaceuticals, Alkermes, Acquisition, Merger, Pharmaceuticals, Hypersomnolence Disorders, SEC Filing, Corporate Integration, Takeover